Home › Trial NCT06102395
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
- Trial IDNCT06102395
- StatusRecruiting
- PhasePhase 3
- Study typeInterventional
- SponsorBeijing Tongren Hospital
- Enrollment272
- Start date2023-05-01
- ConditionsHead and Neck Squamous Cell Carcinoma · Neoadjuvant Therapy · Pembrolizumab
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.